[go: up one dir, main page]

WO2018052356A1 - A dietary supplement for balancing cholesterol. - Google Patents

A dietary supplement for balancing cholesterol. Download PDF

Info

Publication number
WO2018052356A1
WO2018052356A1 PCT/SE2017/050778 SE2017050778W WO2018052356A1 WO 2018052356 A1 WO2018052356 A1 WO 2018052356A1 SE 2017050778 W SE2017050778 W SE 2017050778W WO 2018052356 A1 WO2018052356 A1 WO 2018052356A1
Authority
WO
WIPO (PCT)
Prior art keywords
ester composition
glycerol ester
weight
glyceryl
blood stream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2017/050778
Other languages
French (fr)
Inventor
Thao DUY NGUYEN
Frida FÅK HÅLLENIUS
Margareta Nyman
Maria Petersson
Stefan Lundmark
Alf Gunnarsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perstorp AB
Original Assignee
Perstorp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perstorp AB filed Critical Perstorp AB
Publication of WO2018052356A1 publication Critical patent/WO2018052356A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention refers to a glycerol ester composition comprising glyceryl
  • LDL Low- Density Lipoprotein
  • HDL High-Density Lipoprotein
  • LDL particles are often referred to as "bad cholesterol” because they can transport their content of lipid molecules into artery walls, attract macrophages, and thus drive atherosclerosis.
  • HDL particles are often called “good cholesterol” because they can remove lipids from macrophages in the wall of arteries.
  • HDL low-density lipoprotein particles
  • HDL particles remove fats and cholesterol from cells, including cholesterol within artery wall atheroma, and transport it back to the liver for excretion or re-utilization. This is the reason why cholesterol carried within HDL particles is sometimes called "good cholesterol" despite the fact that it is basically the same as the cholesterol in the LDL particles. Those with higher levels of HDL tend to have fewer problems with cardiovascular diseases, while those with low HDL levels have increased rates for heart disease. Higher HDL levels are correlated with better cardiovascular health. It does, however not appear that further increasing one's HDL levels improves cardiovascular outcomes. The ratio between LDL and HDL cholesterol as well as the total levels of lipoproteins in the blood stream seem to be equally critical factors for avoiding cardiovascular disease and maintaining a good cardiovascular health.
  • the present invention relates to a glycerol ester composition comprising glyceryl monobutyrate, for use in treating systemic low-grade inflammation.
  • Long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis is hereby alleviated. This is achieved through the treatment which decreases the ratio between low density lipoprotein (LDL) and high density lipoprotein (HDL) in the blood stream of a monogastric animal (including human).
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • the glyceryl monobutyrate is preferably administered in the range 0.3 - 0.8 % by weight of the daily food ration for decreasing the LDL/HDL ratio in the blood stream of a monogastric animal (including human).
  • the LDL/HDL ratio in the blood stream is decreased by at least 10%.
  • LDL low levels of HDL and too high levels of LDL is a driving factor behind atherosclerosis. A decrease in the ratio between LDL and HDL is accordingly positive.
  • High fat diets are known to cause dysbiosis, i.e. an imbalance of the microbiota composition in colon and therefore also in the gut metabolites formed, such as short-chain fatty acids (SCFA).
  • SCFA are important substrates for the colon mucosa, especially butyrate.
  • the mucosal permeability may increase, with an increased influx of toxic substances that can cause systemic low-grade inflammation and in the long term metabolic diseases as coronary heart diseases and atheroscleorosis.
  • By supplying a surplus of butyric acid in colon the mucosal permeability may decrease and as a consequence low-grade inflammation and metabolic risk factors connected to this inflammation, (such as decreased cholesterol levels).
  • the invention also relates to a glycerol ester composition comprising glyceryl monobutyrate, for use in treating systemic low-grade inflammation.
  • Long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis is hereby alleviated. This is achieved through the treatment which decreases total cholesterol levels in the blood stream of a monogastric animal (including human).
  • the glyceryl monobutyrate is preferably administered in the range 0.3 - 0.8 % by weight of the daily food ration for decreasing total cholesterol levels in the blood stream of a monogastric animal (including human).
  • the total cholesterol levels in the blood stream is decreased by at least 30%.
  • said glycerol ester composition comprises the reaction product obtained from reacting butyric acid and glycerol at a molar ratio of between 1 : 0.8 and 1 : 1.2.
  • Said glycerol ester composition preferably comprises at least 30% by weight of glyceryl monobutyrate, below 20% by weight of glyceryl dibutyrate and below 5% by weight of glyceryl tributyrate.
  • said glycerol ester composition comprises at least 40% by weight of glyceryl monobutyrate, below 15% by weight of glyceryl dibutyrate and below 2% by weight of glyceryl tributyrate.
  • the amount of free butyric acid in said glycerol ester composition is suitably below 0.5 % by weight.
  • said glycerol ester composition is adsorbed on a carrier, such as a silica carrier, thereby allowing said glycerol ester composition to be distributed as a dry product.
  • a carrier such as a silica carrier
  • the claimed invention is particularly suited for treatment of animals (including human) consuming diets with high fat content.
  • a group of male Wistar rats were randomly divided into two subgroups, group A and group B.
  • Group A and group B were allowed a three day period of acclimatization and were then given the test diet.
  • Group A (control) were given free access to the test diet of table 1 column A while Group B (tested group) were given free access to the test diet of table 1 column B.
  • test groups where allowed free access to their respective diet above for a period of 21 days.
  • test groups also had free access to water.
  • the temperature during the test was 21 °C and a 12 hour day / 12 hour night cycle was applied.
  • composition in accordance with the invention radically lowered the total cholesterol levels in the blood stream of the animal.
  • composition in accordance with the invention significantly decreased the LDL/HDL ratio in the blood stream of the animal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A glycerol ester composition comprising glyceryl monobutyrate, for use in use in treating systemic low-grade inflammation, thereby alleviating long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis by improving a positive balance between low density lipoprotein (LDL) and high density lipoprotein (HDL) in the blood stream of a monogastric animal (including human). The invention also relates to glyceryl monobutyrate, for use in treating systemic low-grade inflammation, thereby alleviating long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis by decreasing total cholesterol levels in the blood stream of a monogastric animal (including human).

Description

A DIETARY SUPPLEMENT FOR BALANCING CHOLESTEROL.
The present invention refers to a glycerol ester composition comprising glyceryl
monobutyrate for balancing cholesterol levels.
The high fat diets of the western world has become a growing problem since several decades. It is part of human nature to eat while food is available and also to prefer food with high energy content. This is a genetically inherited disposition that has served humanity well since before civilization during times when food supply was seasonal and sometimes scarce. In modern time, with all types of food being available out of season and in abundance in the so called developed part of the world, our genetic disposition will become a burden. A majority of us will still select food with high energy value as if we were expecting times of starvation.
Besides known consequences such as obesity and all the health problems that follows with this also clogging of blood vessels known as atherosclerosis is a growing health issue. The latter is a known effect of heightened levels of cholesterol in the blood stream. There is a desire to be able to lower the cholesterol levels in a simple way. Cholesterol is a collective phrase for describing several types of lipoproteins. In the present invention Low- Density Lipoprotein (LDL) and High-Density Lipoprotein (HDL) are of particular interest. LDL, also known as "bad cholesterol" has a particle size of about 220 - 275 Angstrom.
LDL particles pose a risk for cardiovascular disease when they invade the endothelium and become oxidized, since the oxidized forms are more easily retained by proteoglycans. A set of biochemical reactions regulates the oxidation of LDL particles, primarily stimulated by the presence of necrotic cell debris and free radicals in the endothelium. Increased concentrations of LDL particles are strongly associated with accumulation of atherosclerosis within the walls of arteries over time. This will eventually result in sudden plaque ruptures. Even though it may take decades, this can trigger clots within the artery, narrowing or even closing of the arteries, i.e. cardiovascular disease, stroke, and other vascular disease complications.
LDL particles are often referred to as "bad cholesterol" because they can transport their content of lipid molecules into artery walls, attract macrophages, and thus drive atherosclerosis. In contrast, HDL particles are often called "good cholesterol" because they can remove lipids from macrophages in the wall of arteries. In healthy individuals, about 30% of cholesterol carried in the blood stream, along with other fats, is carried by HDL. This is often contrasted with the amount of cholesterol estimated to be carried within low-density lipoprotein particles, LDL.
HDL particles remove fats and cholesterol from cells, including cholesterol within artery wall atheroma, and transport it back to the liver for excretion or re-utilization. This is the reason why cholesterol carried within HDL particles is sometimes called "good cholesterol" despite the fact that it is basically the same as the cholesterol in the LDL particles. Those with higher levels of HDL tend to have fewer problems with cardiovascular diseases, while those with low HDL levels have increased rates for heart disease. Higher HDL levels are correlated with better cardiovascular health. It does, however not appear that further increasing one's HDL levels improves cardiovascular outcomes. The ratio between LDL and HDL cholesterol as well as the total levels of lipoproteins in the blood stream seem to be equally critical factors for avoiding cardiovascular disease and maintaining a good cardiovascular health.
Accordingly the present invention relates to a glycerol ester composition comprising glyceryl monobutyrate, for use in treating systemic low-grade inflammation. Long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis is hereby alleviated. This is achieved through the treatment which decreases the ratio between low density lipoprotein (LDL) and high density lipoprotein (HDL) in the blood stream of a monogastric animal (including human).
The glyceryl monobutyrate is preferably administered in the range 0.3 - 0.8 % by weight of the daily food ration for decreasing the LDL/HDL ratio in the blood stream of a monogastric animal (including human).
The LDL/HDL ratio in the blood stream is decreased by at least 10%.
As discussed above both LDL and HDL will always be present in the blood stream. LDL, "the bad cholesterol", will always be present in higher levels than HDL, "the good cholesterol". Even though there does not seem to be established an ideal best health ratio between LDL and HDL in the blood stream it is known that too low levels of HDL and too high levels of LDL is a driving factor behind atherosclerosis. A decrease in the ratio between LDL and HDL is accordingly positive.
High fat diets are known to cause dysbiosis, i.e. an imbalance of the microbiota composition in colon and therefore also in the gut metabolites formed, such as short-chain fatty acids (SCFA). SCFA are important substrates for the colon mucosa, especially butyrate. At a low formation of colonic butyrate the mucosal permeability may increase, with an increased influx of toxic substances that can cause systemic low-grade inflammation and in the long term metabolic diseases as coronary heart diseases and atheroscleorosis. By supplying a surplus of butyric acid in colon the mucosal permeability may decrease and as a consequence low-grade inflammation and metabolic risk factors connected to this inflammation, (such as decreased cholesterol levels).
The invention also relates to a glycerol ester composition comprising glyceryl monobutyrate, for use in treating systemic low-grade inflammation. Long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis is hereby alleviated. This is achieved through the treatment which decreases total cholesterol levels in the blood stream of a monogastric animal (including human).
The glyceryl monobutyrate is preferably administered in the range 0.3 - 0.8 % by weight of the daily food ration for decreasing total cholesterol levels in the blood stream of a monogastric animal (including human).
The total cholesterol levels in the blood stream is decreased by at least 30%.
According to one embodiment of the invention said glycerol ester composition comprises the reaction product obtained from reacting butyric acid and glycerol at a molar ratio of between 1 : 0.8 and 1 : 1.2.
Said glycerol ester composition preferably comprises at least 30% by weight of glyceryl monobutyrate, below 20% by weight of glyceryl dibutyrate and below 5% by weight of glyceryl tributyrate.
According to an even more preferred embodiment of the invention said glycerol ester composition comprises at least 40% by weight of glyceryl monobutyrate, below 15% by weight of glyceryl dibutyrate and below 2% by weight of glyceryl tributyrate. The amount of free butyric acid in said glycerol ester composition is suitably below 0.5 % by weight.
According to one embodiment of the invention said glycerol ester composition is adsorbed on a carrier, such as a silica carrier, thereby allowing said glycerol ester composition to be distributed as a dry product.
The claimed invention is particularly suited for treatment of animals (including human) consuming diets with high fat content.
A study was performed on rat fed a high fat diet.
A group of male Wistar rats were randomly divided into two subgroups, group A and group B. Group A and group B were allowed a three day period of acclimatization and were then given the test diet. Group A (control) were given free access to the test diet of table 1 column A while Group B (tested group) were given free access to the test diet of table 1 column B.
Table 1.
Figure imgf000006_0001
As said above, both test groups where allowed free access to their respective diet above for a period of 21 days. In addition the test groups also had free access to water. The temperature during the test was 21 °C and a 12 hour day / 12 hour night cycle was applied.
After the test period the rats were anaesthetised for tissue harvesting. From blood samples of the test subjects the levels of cholesterols were analysed and compared between the two test groups. See diagram A (total cholesterol) and diagram B (LDL/HDL ratio). Diagram A
Figure imgf000007_0001
It is shown that the administered composition in accordance with the invention radically lowered the total cholesterol levels in the blood stream of the animal.
Diagram B
Figure imgf000007_0002
It is shown that the administered composition in accordance with the invention significantly decreased the LDL/HDL ratio in the blood stream of the animal.
The collected effect of both lowering the total cholesterol levels and also changing the LDL/HDL ratio in favour of HDL is regarded as very positive results. A follow up study was performed to ascertain the effect of different dosage levels. The same diet as disclosed in table 1 was used but with glycerol monobutyrate added at 0.25, 075 and 1.5 % dwb. Even though the results of this dosage study was not considered statistically significant between the different levels there was a clear indication that peak efficiency was 0.75% of glycerol monobutyrate dwb dosing. The dose levels 0.25% and 1.5% was slightly less effective considering the lowering of total cholesterol levels in the blood stream. The same were found for HDL levels as well as LDL/HDL ratio in the blood stream where the 0.75% was found to be slightly more efficient in lowering levels and ratio than the 0.25% and 1.5% dosing.

Claims

1. A glycerol ester composition comprising glyceryl monobutyrate, for use in treating systemic low-grade inflammation, thereby alleviating long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis by decreasing the ratio between low density lipoprotein (LDL) and high density lipoprotein (HDL) in the blood stream of a monogastric animal (including human).
2. A glycerol ester composition comprising glyceryl monobutyrate, for use in in treating systemic low-grade inflammation, thereby alleviating long term sequelae metabolic diseases comprising coronary heart diseases and atheroscleorosis by decreasing total cholesterol levels in the blood stream of a monogastric animal (including human).
3. A glycerol ester composition according to claim 1, wherein glyceryl monobutyrate in the range 0.3 - 0.8 % by weight of the daily food ration is administered for decreasing the LDL/HDL ration in the blood stream of a monogastric animal (including human).
4. A glycerol ester composition according to claim 2, wherein glyceryl monobutyrate in the range 0.3 - 0.8 % by weight of the daily food ration is administered for decreasing total cholesterol levels in the blood stream of a monogastric animal (including human).
5. A glycerol ester composition according to claim 1 or 3, wherein the LDL/HDL ratio in the blood stream is decreased by at least 10%.
6. A glycerol ester composition according to claim 2 or 4, wherein the total cholesterol levels in the blood stream is decreased by at least 30%.
7. A glycerol ester composition according to claim 1 or 2, wherein said glycerol ester composition comprises the reaction product obtained from reacting butyric acid and glycerol at a molar ratio of between 1 : 0.8 and 1 : 1.2.
8. A glycerol ester composition according to claim 1 or 2, wherein said glycerol ester composition comprises at least 30% by weight of glyceryl monobutyrate, below 20% by weight of glyceryl dibutyrate and below 5% by weight of glyceryl tributyrate.
9. A glycerol ester composition according to claim 1 or 2, wherein said glycerol ester composition comprises at least 40% by weight of glyceryl monobutyrate, below 15% by weight of glyceryl dibutyrate and below 2% by weight of glyceryl tributyrate.
10. A glycerol ester composition according to claim 1 or 2, wherein the amount of free butyric acid in said glycerol ester composition is below 0.5 % by weight.
11. A glycerol ester composition according to claim 1 or 2, wherein said glycerol ester composition is adsorbed on a carrier, such as a silica carrier, thereby allowing said glycerol ester composition to be distributed as a dry product.
PCT/SE2017/050778 2016-09-19 2017-07-13 A dietary supplement for balancing cholesterol. Ceased WO2018052356A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1630227 2016-09-19
SE1630227-5 2016-09-19

Publications (1)

Publication Number Publication Date
WO2018052356A1 true WO2018052356A1 (en) 2018-03-22

Family

ID=61619666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2017/050778 Ceased WO2018052356A1 (en) 2016-09-19 2017-07-13 A dietary supplement for balancing cholesterol.

Country Status (1)

Country Link
WO (1) WO2018052356A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127182A1 (en) * 2018-12-18 2020-06-25 Société des Produits Nestlé S.A. Mixed triglyceriges
WO2020226548A1 (en) * 2019-05-09 2020-11-12 Perstorp Ab Antioxidant composition for animal feed

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306729A (en) * 1992-02-25 1994-04-26 Joslin Diabetes Center Method for effecting vasodilation with monoglycerides
WO2010106488A2 (en) * 2009-03-16 2010-09-23 Fernando Cantini Compositions containing c1 to c7 organic acid monoglycerides and glycerol, their preparation and use as antibacterials and anti-mould agents
CN102366413A (en) * 2011-10-10 2012-03-07 上海交通大学 Application of glyceryl tributyrate in preparation of drug for treating cardiovascular disease
WO2015057121A1 (en) * 2013-10-14 2015-04-23 Perstorp Ab Composition preventing necrotic enteritis in galloanserans
CN105166415A (en) * 2015-10-09 2015-12-23 武汉轻工大学 Different-chain-length fat composition for improving pig growth and intestinal health and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306729A (en) * 1992-02-25 1994-04-26 Joslin Diabetes Center Method for effecting vasodilation with monoglycerides
WO2010106488A2 (en) * 2009-03-16 2010-09-23 Fernando Cantini Compositions containing c1 to c7 organic acid monoglycerides and glycerol, their preparation and use as antibacterials and anti-mould agents
CN102366413A (en) * 2011-10-10 2012-03-07 上海交通大学 Application of glyceryl tributyrate in preparation of drug for treating cardiovascular disease
WO2015057121A1 (en) * 2013-10-14 2015-04-23 Perstorp Ab Composition preventing necrotic enteritis in galloanserans
CN105166415A (en) * 2015-10-09 2015-12-23 武汉轻工大学 Different-chain-length fat composition for improving pig growth and intestinal health and application thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AGUILAR, E.C. ET AL.: "Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFkB activation", NUTRITION, METABOLISM & CARDIOVASCULAR DISEASE, vol. 24, no. 6, 2014, pages 606 - 613, XP029029918 *
AGUILAR, E.C. ET AL.: "Oral butyrate reduces oxidative stress in atherosclerosis lesion sites by a mechanism involving NADPH oxidase down-regulation in endothelisal cells", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 34, 2016, pages 99 - 105, XP029639338 *
ANTONGIOVANNI, M. ET AL.: "Monobutyrine: a novel feed additive in the diet of broiler chickens", ITALIAN JOURNAL OF ANIMAL SCIENCE, vol. 9, no. 4, 2010, pages 369 - 371, XP055127023 *
HARA, H. ET AL.: "Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine", JOURNAL OF NUTRITION, vol. 129, no. 5, 1999, pages 942 - 948, XP055483645 *
MARCIL, V. ET AL.: "Modulation of lipid synthesis, apolipoprotein biogenesis, and lipoprotein assembly by butyrate", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 283, 2002, pages G340 - G346, XP055457302 *
WILKISON, W. ET AL.: "Biosynthesis of the vasoactive lipid monobutyrin. Central role of diacylglycerol", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 4, 1993, pages 2844 - 2849, XP055483643 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127182A1 (en) * 2018-12-18 2020-06-25 Société des Produits Nestlé S.A. Mixed triglyceriges
CN113194733A (en) * 2018-12-18 2021-07-30 雀巢产品有限公司 Mixed triglycerides
AU2019409543B2 (en) * 2018-12-18 2025-05-29 Société des Produits Nestlé S.A. Mixed triglyceriges
US12527761B2 (en) 2018-12-18 2026-01-20 Societe Des Produits Nestle S.A. Mixed triglycerides
WO2020226548A1 (en) * 2019-05-09 2020-11-12 Perstorp Ab Antioxidant composition for animal feed

Similar Documents

Publication Publication Date Title
Berger et al. Plant sterols: factors affecting their efficacy and safety as functional food ingredients
JP6491189B2 (en) Compositions and methods for suppressing appetite, promoting weight loss, or treating obesity that result in enhanced and sustained ketosis
Vijaimohan et al. Beneficial effects of alpha linolenic acid rich flaxseed oil on growth performance and hepatic cholesterol metabolism in high fat diet fed rats
ES2822178T3 (en) Dietary formulations that promote tissue / organ regeneration
Derouiche et al. Nutritional intervention study with argan oil in man: effects on lipids and apolipoproteins
Majid et al. Effects of natural honey on blood glucose and lipid profile in young healthy Pakistani males
Zhou et al. Dietary fat composition influences tissue lipid profile and gene expression in Fischer-344 rats
AU2004210244C1 (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides
Samaha et al. Low-carbohydrate diets, obesity, and metabolic risk factors for cardiovascular disease
Cominacini et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers
WO2018052356A1 (en) A dietary supplement for balancing cholesterol.
CN102202661A (en) Method of reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for the treatment of atherosclerosis
Fedorova-Dahms et al. A 3-week dietary bioequivalence study in preweaning farm piglets of two sources of docosahexaenoic acid produced from two different organisms
Lu et al. Maternal docosahexaenoic acid supplementation during lactation improves exercise performance, enhances intestinal glucose absorption and modulates gut microbiota in weaning offspring mice
Ebaid et al. Effects of digitonin on hyperglycaemia and dyslipidemia induced by high-sucrose intake
Jia et al. Hypocholesterolaemic effects of plant sterol analogues are independent of ABCG5 and ABCG8 transporter expressions in hamsters
K Ramadan et al. Role of pumpkin seed oil on some cardiovascular and renal aspects in adult male albino rats
CN104740090A (en) Functional grease composition with improvement effects on atherosclerosis
Iwamoto et al. Differential effect of walnut oil and safflower oil on the serum cholesterol level and lesion area in the aortic root of apolipoprotein E-deficient mice
Zommara et al. Antiatherogenic effect of Tiger nut tubers (Cyperus esculentus L.) supplemented diet in apolipoprotein E knockout mice
Wong et al. Coconut milk gavage enhanced fecal bile excretion by modulating hepatic Fxr expression but failed to improve fasting serum cholesterol profile in C57BL/6 mice
Abdel-Rahman et al. The synthesis and characterization of gold nanoparticles with polyunsaturated oils contribute to hypolipidemic and anti-obesity activities in vivo.
Brown Bioactive oxidised products of omega-6 and omega-3, excess oxidative stress, oxidised dietary intake and antioxidant nutrient deficiencies, in the context of a modern diet
Khan et al. Thermally oxidized olive oil oroduces biochemical, physiological effects and fatty liver in rats
WO2018052357A1 (en) A dietary supplement for alleviating chronic inflammation in colon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17851176

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17851176

Country of ref document: EP

Kind code of ref document: A1